Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px
Person › Details

Cyrill Zimmermann (Adamant Biomedical Investments AG)

Zimmermann, Cyrill (Bellevue Group 201409 CEO of Adamant Biomedical Investments AG)

 

Organisation Organisation Adamant Biomedical Investments AG
  Group Bellevue (Group)
Products Product venture capital
  Product 2 medical device
     

Bellevue Asset Management AG. (9/5/14). "Press Release: Bellevue Group Acquires Adamant Biomedical Investments AG from Zürcher Kantonalbank and Strenghtens Its Leading Position in the Market for Healthcare Investing". Küsnacht.

o Acquisition of investment funds and mandates with assets under management of CHF 831 million, bringing total assets under management at Bellevue Asset Management to CHF 3.9 billion

o Integration of Adamant enhances Bellevue Asset Management's investment expertise and strengthens its leading position as a provider of healthcare investment solutions

o Further growth opportunities for the investment funds managed by Adamant Biomedical Investments AG thanks to Bellevue Asset Management's international distribution network

o Long-standing and successful collaboration between Adamant Biomedical Investments AG and Zürcher Kantonalbank will continue


Subject to the approval of the competent authority FINMA, Bellevue Group is planning to acquire full ownership of Adamant Biomedical Investments AG (Adamant) effective September 30, 2014. All of Adamant's investment funds and its mandate business, comprising combined investment assets of CHF 831 million focused on the healthcare segment, will be acquired and Adamant's nine employees will join Bellevue Asset Management.

Urs Baumann, CEO of Bellevue Group, remarks: "Acquiring Adamant allows us to broaden Bellevue Group's recurring revenue base significantly and expand our leadership in the market for healthcare investment solutions and services."

Iwan Deplazes, Head of Asset Management of Zürcher Kantonalbank, comments: "We are happy to have found a competent partner of international prestige who can build on and expand Adamant's product portfolio and investment competencies to the advantage of all stakeholders."

"Adamant complements and expands our investment competencies and our market presence in an ideal way. We will benefit from better coverage of our home Swiss market and from a greater range of international business opportunities. We're looking forward to working side by side with Adamant's team and presenting the new investment resources to our clients," adds André Rüegg, CEO of Bellevue Asset Management.

"Bellevue Asset Management's international business model creates a host of new and attractive business opportunities that we plan to take advantage of with an entrepreneurial mindset," remarks Dr. Cyrill Zimmermann, CEO of Adamant.


Organizational integration to take place on January 1, 2015

Bellevue Asset Management and Adamant will be merged on January 1, 2015, to optimally exploit all product and market synergies. Under the management of Dr. Cyrill Zimmermann, the Adamant team will assume responsibility for the healthcare investment funds and mandates offered by Bellevue, in addition to Adamant's existing range of products. Adamant products will continue to be marketed under the Adamant brand. BB Biotech AG, the flagship product of Bellevue Group, will continue to be managed and developed by the successful, long-standing team headed by Dr. Daniel Koller.


Contacts:

Media Relations:

André Rüegg, CEO Bellevue Asset Management
Telephone +41 44 267 67 00, Fax +41 44 267 67 01, aru@bellevue.ch

Dr. Cyrill Zimmermann, CEO Adamant Biomedical Investments AG
Telephone +41 61 275 92 11, Fax +41 61 275 92 01, cyrill.zimmermann@adamantinvest.com

Zürcher Kantonalbank, Media Relations
Telephone +41 44 292 29 79, Fax +41 44 292 38 23, medien@zkb.ch

Investor Relations:

Daniel Koller, CFO Bellevue Group
Telephone +41 44 267 67 00, Fax +41 44 267 67 01, ir@bellevue.ch


Bellevue Group

Bellevue Group is an independent Swiss financial boutique listed on the SIX Swiss Exchange. Established in 1993, the company and its approximately 80 employees are specialists in the fields of Brokerage, Corporate Finance and Asset Management. Bellevue Group includes the two subsidiaries Bank am Bellevue and Bellevue Asset Management. The bank boasts superb knowledge of the Swiss stock and bond market and offers independent research opinions and recommendations as well as viable solutions for capital market transactions. Bellevue Asset Management is focused on selected active equity investment strategies in growing markets, in healthcare industries as well as in other special themes such as entrepreneur-led companies.


Adamant Biomedical Investments AG

Adamant Biomedical Investments AG is an asset manager exclusively focused on healthcare. Its dedicated specialists have many years of experience in the fields of healthcare, investment research and portfolio management. Adamant's investment universe is the entire healthcare industry: Pharma, biotech, medtech, and generics as well as healthcare services and providers. Adamant was established in 2000 and is regulated by the Swiss Financial Market Supervisory Authority FINMA.


Zürcher Kantonalbank

Zürcher Kantonalbank is the market-leading full-service bank in the Zurich region and has a national as well as an international focus. With total assets of CHF 149.7 bn, Zürcher Kantonalbank is the largest of the cantonal banks and Switzerland's fourth-largest bank overall. Building on its extensive competence in the mortgage and credit businesses, it is also very successfully positioned in the investment and retirement-savings sector and with assets under management totaling CHF 191.9 bn today ranks among Switzerland's largest asset managers. As an independent institution incorporated under public law in the canton of Zurich, it benefits from a government guarantee. The canton provides a guarantee for all liabilities of Zürcher Kantonalbank should the latter's resources prove inadequate. Zürcher Kantonalbank is one of the few banks in the world to retain a first-class rating (AAA or Aaa) from rating agencies Standard & Poor's, Moody's, and Fitch.

   
Record changed: 2017-04-09

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px


More documents for Cyrill Zimmermann


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px




» top